Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus
Go back to Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus| CARA THERAPEUTICS (NASDAQ: CARA) | Delayed: 5.32 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.32 | 52 Week High | $17.69 | |||
| Open | $5.32 | 52 Week Low | $4.26 | |||
| Day High | $5.32 | P/E | N/A | |||
| Day Low | $5.32 | EPS | $-0.42 | |||
| Volume | 7,304 | |||||
| FRESENIUS MEDICAL CARE AG & CO. KGAA (NYSE: FMS) | Delayed: 22.45 -0.21 (0.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $22.66 | 52 Week High | $47.52 | |||
| Open | $22.76 | 52 Week Low | $38.61 | |||
| Day High | $22.78 | P/E | N/A | |||
| Day Low | $22.44 | EPS | $0.00 | |||
| Volume | 804,775 | |||||
